TrialGut2019
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
Roser Pinyol et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
194 papers cite itlatest 60 shown
this paperpooled ittrialcites it